Back to results
US 6,280,731 B1Granted
Antithrombotic agent and anti-von willebrand factor monoclonal antibody
AssigneeAjinomoto Co., Inc.
InventorsMitsuyo Nagano, Hiroshi Yamamoto, Morikazu Kito, Ryota Yoshimoto, Tsuyoshi Kobayashi
Life of this patent
Estimating the term…
Abstract
A monoclonal antibody, which has reactivity with human von Willebrand factor, which has action to inhibit RIPA (ristocetin-induced platelet aggregation), BIPA (botrocetin-induced platelet aggregation), and SIPA (shear stress-induced platelet aggregation) of human platelet, and which does not express bleeding action in an medicinally effective dose to exhibit antithrombotic action, is used as an active ingredient of an antithrombotic agent.
Claims4
A monoclonal antibody having the following properties:
- (a) the monoclonal antibody binds to human von Willebrand factor;
- (b) the monoclonal antibody substantially completely inhibits ristocetin-dependent binding and substantially completely inhibits botrocetin-dependent binding of human von Willebrand factor to human platelets at an antibody concentration of 10 μg/ml;
- (c) the monoclonal antibody inhibits RIPA (ristocetin-induced platelet aggregation) and BIPA (botrocetin-induced platelet aggregation) of guinea pig platelets;
- and
- (d) the monoclonal antibody exhibits strong antithrombotic action in vivo in guinea pig, but it does not cause bleeding in a medicinally effective dose to exhibit antithrombotic action.
2 more elements
Dependencies are inferred from the claim text.